473 related articles for article (PubMed ID: 28950295)
21. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Feng Q; Wei Y; Ren L; Zheng P; Yu Y; Ye Q; Ding J; Chen J; Chang W; Zhong Y; Zhu D; Lin Q; Yang L; Qin X; Xu J
Oncotarget; 2016 Mar; 7(10):11380-96. PubMed ID: 26863631
[TBL] [Abstract][Full Text] [Related]
24. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Geredeli C; Yasar N
World J Surg Oncol; 2018 Mar; 16(1):67. PubMed ID: 29587749
[TBL] [Abstract][Full Text] [Related]
25. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
26. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
28. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
Bokemeyer C; Köhne CH; Ciardiello F; Lenz HJ; Heinemann V; Klinkhardt U; Beier F; Duecker K; van Krieken JH; Tejpar S
Eur J Cancer; 2015 Jul; 51(10):1243-52. PubMed ID: 25937522
[TBL] [Abstract][Full Text] [Related]
29. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
30. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
31. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
[TBL] [Abstract][Full Text] [Related]
32. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
33. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
34. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
35. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
36. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Láng I; Köhne CH; Folprecht G; Rougier P; Curran D; Hitre E; Sartorius U; Griebsch I; Van Cutsem E
Eur J Cancer; 2013 Jan; 49(2):439-48. PubMed ID: 23116683
[TBL] [Abstract][Full Text] [Related]
37. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line
Hill AG; Findlay MP; Burge ME; Jackson C; Alfonso PG; Samuel L; Ganju V; Karthaus M; Amatu A; Jeffery M; Bartolomeo MD; Bridgewater J; Coveler AL; Hidalgo M; Kapp AV; Sufan RI; McCall BB; Hanley WD; Penuel EM; Pirzkall A; Tabernero J
Clin Cancer Res; 2018 May; 24(10):2276-2284. PubMed ID: 29506988
[No Abstract] [Full Text] [Related]
38. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
39. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
40. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]